Axovant Sciences Ltd.
Quick facts
Phase 3 pipeline
- RVT-101 · Neurology
RVT-101 is a small molecule that targets the tau protein to treat neurodegenerative diseases.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: